Itamar Medical Gains Most in 4 Months on Chinese Approval

Itamar Medical Ltd. rose the most in almost four months after the maker of medical diagnostic equipment said two of its products were approved for distribution in China.

The shares gained 5.6 percent, the biggest increase since Dec. 7, to 2.08 shekels at the 4:30 p.m. close in Tel Aviv.

WatchPAT, a device for diagnosing sleep apnea, and the company’s non-invasive cardiovascular device EndoPAT can now be sold in the Asian country.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE